Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248882 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP2C19TACR1SMN1; SMN2 | |
| SCHEMBL2785511 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP2C19TACR1SMN1; SMN2 | |
| SCHEMBL2333573 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP2C19TACR1SMN1; SMN2 | |
| SCHEMBL3282010 | 0.92 | SLC6A2 (0.52) | CYP2D6CYP1A2CYP2C19TACR1SLC6A2 | |
| SCHEMBL12706002 | 0.90 | CYP1A2 (0.62) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 | |
| SCHEMBL10804153 | 0.90 | CYP1A2 (0.62) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 | |
| Lactic Acid SCHEMBL7771136 | 0.87 | PSMB5 (0.48) | CYP2D6CYP1A2CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL468022 | 0.85 | EPHX1 (0.61) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 | |
| SCHEMBL272604 | 0.85 | EPHX1 (0.61) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 | |
| SCHEMBL3451169 | 0.85 | EPHX1 (0.61) | CYP2D6CYP1A2CYP2C19SLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754740-B2 | 1H-indole-3-carboxylic acid derivatives and their use as PPAR agonists | MERCK PATENT GMBH (DE) | 2010-07-13 | — | — | US | claimed |
| EP-1142892-A1 | PROCESSES FOR THE PREPARATION OF NOVEL NAPHTHYRIDINE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2001-10-10 | — | — | EP | claimed |
| US-20230312486-A1 | POLYMORPHIC FORMS OF A ROR INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION | GLENMARK SPECIALTY S.A. (CH) | 2023-10-05 | — | — | US | disclosed |
| CN-116669733-A | Polymorphic forms of rorgamma inhibiting compounds and methods of making the same | 格兰马克专业公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4208449-A1 | POLYMORPHIC FORMS OF A RORGAMMA INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION | Glenmark Specialty S.A. (CH) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022049534-A1 | POLYMORPHIC FORMS OF A RORΓ INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION | GLENMARK SPECIALTY S.A. (CH) | 2022-03-10 | — | — | WO | disclosed |
| EP-2247292-B1 | PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2017-04-12 | — | — | EP | disclosed |
| EP-2867240-B1 | THIENOPYRIDONE DERIVATIVES USEFUL AS ACTIVATORS OF AMPK | POXEL (FR) | 2016-09-14 | — | — | EP | disclosed |
| US-9365584-B2 | Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof | POXEL (FR) | 2016-06-14 | — | — | US | disclosed |
| EP-2262500-B1 | THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS | MERCK PATENT GMBH (DE) | 2016-04-27 | — | — | EP | disclosed |
| US-9284329-B2 | Thienopyridone derivatives useful as activators of AMPK | POXEL (FR) | 2016-03-15 | — | — | US | disclosed |
| US-6025531-A | REACTING A PROCHIRAL KETONE WITH A MIXTURE BORON-CONTAINING COMPOUNDS HAVING A BORANE REACTION PRODUCT FROM OPTICALLY ACTIVE BETA-AMINOALCOHOL AND A BORON HYDRIDE OR A METAL BOROHYDRIDE, AND AN OPTICALLY ACTIVE OXAZABOROLIDINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-02-15 | — | — | US | disclosed |
| US-5801280-A | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-09-01 | — | — | US | disclosed |
| EP-0736509-A2 | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-10-09 | — | — | EP | disclosed |
| US-5510519-A | OPTICAL RESOLUTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-04-23 | — | — | US | disclosed |
| EP-0508307-B1 | Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound | SUMITOMO CHEMICAL CO (JP) | 1995-11-29 | — | — | EP | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| US-5298660-A | Compound containing an assymetrical carbon atom | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0508307-A2 | Optically active secondary amine compound; process for producing optically active secondary amine compound and process for producing optically active carboxylic acid by using said compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-10-14 | — | — | EP | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312486-A1 | POLYMORPHIC FORMS OF A ROR INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION | RORA, RORB, RORC | CYP2D6 105/4885CYP1A2 51/4885CYP2C19 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.